Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, now LeonaBio, reports clinical-stage biopharmaceutical developments centered on novel therapeutics for diseases with high unmet medical needs. Recent company updates reflect the completed name change, the shift to the LONA ticker, and the acquired rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator for metastatic breast cancer.
The company’s historical Athira updates also cover small-molecule candidates designed to modulate the neurotrophic hepatocyte growth factor system, including ATH-1105 for neurodegenerative diseases such as ALS. Recurring announcements include clinical data presentations, operating and financial results, business updates, capital-structure actions such as the reverse stock split, and governance matters tied to stockholder approvals.
Athira Pharma (NASDAQ: ATHA) announced a proposed settlement for stockholder derivative actions. The settlement, preliminarily approved by the U.S. District Court for the Western District of Washington, involves adopting corporate governance reforms and paying legal fees and service awards to lead plaintiffs. A final approval hearing is scheduled for July 18, 2024. Relevant documents have been posted on Athira's Investor Relations website.
Athira Pharma (NASDAQ: ATHA) released its Q1 2024 financial results and highlighted pipeline and business updates. The company is anticipating topline data from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for Alzheimer's disease in H2 2024. They've also filed an IND application for ATH-1105 for ALS treatment and plan a first-in-human study in Q2 2024. Financially, Athira reported a net loss of $26.3 million, or $0.69 per share, compared to $27.8 million, or $0.73 per share, in Q1 2023. Cash reserves stand at $122.1 million, down from $147.4 million in December 2023. R&D expenses were $21.2 million, while G&A expenses dropped to $6.5 million. The company remains focused on advancing its small molecule drug candidates targeting the HGF system to treat neurodegenerative diseases.
Summary: Athira Pharma, Inc. (NASDAQ: ATHA) will be participating in the Sidoti May 2024 Virtual Investor Conference and The Citizens JMP Life Sciences Conference in May. The Company management will present at these conferences to discuss their focus on developing small molecules to restore neuronal health and slow neurodegeneration. Live webcasts and archived replays will be available on the Athira website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.